Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Novel combination therapies for the treatment of non-Hodgkin lymphoma

Andrew Davies • 11 Jun 2015
EHA 2015
Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma Bendamustine Cyclophosphamide Doxorubicin Prednisone Rituximab Venetoclax Vincristine

At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, summarizes the development of novel combination therapies for the treatment of non-Hodgkin lymphoma (NHL), including venetoclax plus bendamustine and rituximab for patients with relapsed or refractory NHL, and subcutaneous rituximab in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy for patients with previously untreated diffuse large B-cell lymphoma.

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals